argenx, headquartered in Boston, Massachusetts, focuses on antibody‑based medicines for oncology and autoimmune diseases. The company develops therapies targeting rare conditions such as myasthenia gravis, pemphigus vulgaris, immune thrombocytopenia, acute myeloid leukemia, high‑risk myelodysplastic syndromes, and chronic inflammatory demyelinating polyneuropathy, with a strong emphasis on immunotherapy.
With a workforce of 1,000–5,000 employees, argenx was founded in 2008 and generates annual revenue between $1 billion and $5 billion. Its leadership includes Chuck Saunders (Global Head, Trademarks & Brand Protection), Staci Graber (Head of Employee Communications and Engagement), Kenneth Bachek (Head Clinical Site Agreements), Lisa Wright (Digital Technology Product Owner – Commercial Planning & Readiness), Daniel (Head, Medical Affairs & Evidence Generation Strategy and Planning), Rikki Allard (Senior Manager, Commercial FP&A), Jarred Kiel (Associate Director, Access and Reimbursement), David Grabke (Territory Business Manager), Tom Peddicord (Senior Director, Payer & HEOR MSLs and Immunology MSLs Lead), Starla Swaim (Director, Medical Science Liaison – Immunology (Rheumatology & Dermatology)), Babajide Bayo (Senior IT Consultant/ Leader), Deepika Cattry (Director, US Commercial HCP Marketing – Rheumatology), Casey Goodnough (Nurse Case Manager), Eiji (Territory Science Manager), Adam (Business Manager) and Priscilla Julian (Nurse Case Manager).